Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Patients with chemo refractory CLL have a poor prognosis. 2 independent mechanisms are
attributed to the development of chemoresistance in CLL. The first is a shift in the balance
between pro- and anti-apoptotic regulators. The second mechanism is based on acquired
mutations resulting in a dysfunctional p53 response. Recent studies indicate that the
tyrosine kinase inhibitor dasatinib acts synergistically with both purine analogies and
alkylating agents. Also, dasatinib has the potency to restore the apoptotic balance of CLL
cells.
Hypothesis: Dasatinib will be clinically active in chemo-refractory CLL patients and will act
synergistically with the purine-analogue fludarabine.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)